Skip to main content

Table 1 Characteristics of women with endometrial cancer

From: Incidence and risk of venous thromboembolism according to primary treatment type in women with endometrial cancer: a population-based study

 

The total follow-up period

The first six months

VTE (−)

VTE (+)

Total

 

VTE (−)

VTE (+)

Total

 

n = 25,899 (98.6%)

n = 357 (1.4%)

n = 26,256 (100%)

P value

n = 26,114 (99.5%)

n = 142 (0.5%)

n = 26,256 (100%)

P value

Mean age (years), mean ± SE

54.17 ± 0.1

59.25 ± 0.6

54.24 ± 0.1

<.001 a

54.21 ± 0.1

58.35 ± 0.9

54.24 ± 0.1

<.001 a

SES, n (%)

   

0.101

   

0.61

 Mid- or high- SES

24,767 (95.6)

335 (93.8)

25,102 (95.6)

 

24,965 (95.6)

137 (96.5)

25,102 (95.6)

 

 Low SES

1132 (4.4)

22 (6.2)

1154 (4.4)

 

1149 (4.4)

5 (3.5)

1154 (4.4)

 

CCI, n (%)

   

<.001

   

0.695

 0

14,299 (55.2)

159 (44.5)

14,458 (55.1)

 

14,387 (55.1)

71 (50)

14,458 (55.1)

 

 1

3464 (13.4)

48 (13.4)

3512 (13.4)

 

3491 (13.4)

21 (14.8)

3512 (13.4)

 

 2

4688 (18.1)

76 (21.3)

4764 (18.1)

 

4738 (18.1)

26 (18.3)

4764 (18.1)

 

 3

1366 (5.3)

24 (6.7)

1390 (5.3)

 

1381 (5.3)

9 (6.3)

1390 (5.3)

 

 Over 4

2082 (8)

50 (14)

2132 (8.1)

 

2117 (8.1)

15 (10.6)

2132 (8.1)

 

Year of endometrial cancer diagnosis, n (%)

   

0.101

   

0.016

 2009

1991 (7.7)

20 (5.6)

2011 (7.7)

 

2007 (7.7)

4 (2.8)

2011 (7.7)

 

 2010

2099 (8.1)

25 (7)

2124 (8.1)

 

2116 (8.1)

8 (5.6)

2124 (8.1)

 

 2011

2238 (8.6)

45 (12.6)

2283 (8.7)

 

2268 (8.7)

15 (10.6)

2283 (8.7)

 

 2012

2319 (9)

32 (9)

2351 (9)

 

2342 (9)

9 (6.3)

2351 (9)

 

 2013

2508 (9.7)

37 (10.4)

2545 (9.7)

 

2537 (9.7)

8 (5.6)

2545 (9.7)

 

 2014

2553 (9.9)

38 (10.6)

2591 (9.9)

 

2583 (9.9)

8 (5.6)

2591 (9.9)

 

 2015

2686 (10.4)

42 (11.8)

2728 (10.4)

 

2707 (10.4)

21 (14.8)

2728 (10.4)

 

 2016

3081 (11.9)

47 (13.2)

3128 (11.9)

 

3106 (11.9)

22 (30)

3128 (11.9)

 

 2017

3326 (12.8)

41 (11.5)

3367 (12.8)

 

3342 (12.8)

25 (17.6)

3367 (12.8)

 

 2018

3098 (12)

30 (8.4)

3128 (11.9)

 

3106 (11.9)

22 (15.5)

3128 (11.9)

 

Primary treatments b, n (%)

   

0.1

   

< 0.001

 No treatement c

5268 (20.3)

70 (19.6)

5338 (20.3)

 

5307 (20.3)

31 (20)

5338 (20.3)

 

 Surgery d

17,386 (67.1)

231 (64.7)

17,617 (67.1)

 

17,509 (67.1)

108 (69.7)

17,617 (67.1)

 

 Radiotherapy ± chemotherapy

544 (2.1)

6 (1.7)

550 (2.1)

 

546 (2.1)

4 (2.6)

550 (2.1)

 

 Chemotherapy

723 (2.8)

18 (5)

741 (2.8)

 

729 (2.8)

12 (7.7)

741 (2.8)

 

Hormone therapy

1978 (7.6)

32 (9)

2010 (7.7)

 

2010 (7.7)

0 (0)

2010 (7.7)

 

Surgery, n (%)

 Total hysterectomy

9874 (56.8)

113 (48.9)

9987 (56.7)

0.016

9932 (56.7)

55 (50.9)

9987 (56.7)

0.225

 Radical hysterectomy

7512 (43.2)

118 (51.1)

7630 (43.3)

0.016

7577 (43.3)

53 (49.1)

7630 (43.3)

0.225

Radiotherapy, n (%)

 CCRT

16 (2.9)

1 (16.7)

17 (0)

0.172 e

17 (3.1)

0 (0)

17 (0)

1 e

 EBRT

306 (56.3)

5 (83.3)

311 (86.9)

0.24 e

308 (56.4)

3 (75)

311 (86.9)

0.637 e

 Brachytherapy

313 (57.5)

2 (33.3)

315 (37.4)

0.41 e

314 (57.5)

1 (25)

315 (37.4)

0.318 e

Chemotherapy, n (%)

 Platinum (cisplatin, carboplatin)

203 (48.2)

11 (61.1)

214 (48.7)

0.442

506 (69.6)

8 (66.7)

514 (69.6)

0.764 e

 Other agents

218 (51.8)

7 (38.9)

225 (51.3)

0.426

221 (30.4)

4 (33.3)

225 (30.4)

0.761 e

 Bevacizumab

16 (3.8)

0 (0)

16 (3.6)

1 e

16 (2.2)

0 (0)

16 (2.3)

1 e

Hormone therapy

 Progestins

1823 (74.6)

29 (72.5)

1852 (74.5)

0.736 e

1852 (74.5)

0 (0)

1852 (74.5)

1 e

 Tamoxifen

49 (2)

2 (5)

51 (2.1)

0.194 e

51 (2.1)

0 (0)

51 (2.1)

1 e

 Progestins and Tamoxifen

33 (1.3)

2 (5)

35 (1.4)

0.106 e

35 (1.4)

0 (0)

35 (1.4)

1 e

 Aromatase inhibitors

69 (2.8)

4 (10)

73 (2.9)

0.027 e

73 (2.9)

0 (0)

73 (2.9)

1 e

 Gonadotropin-releasing hormone agonists

21 (0.9)

1 (2.5)

22 (0.9)

0.299 e

22 (0.9)

0 (0)

22 (0.9)

1 e

 Levonorgestrel-releasing intrauterine system

450 (18.4)

2 (5)

452 (18.2)

0.027

452 (18.2)

0 (0)

452 (18.2)

1 e

Time between primary treatments and VTE diagnosis (days), mean ± SE

 

526.8 ± 46.4

   

79.9 ± 7.5

  
  1. CCI Charlson comorbidity index; CCRT concurrent chemoradiation therapy; EBRT external beam radiation therapy; HIRA health insurance review & assessment Service; n number; SES socioeconomic status; VTE venous thromboembolism
  2. All values are expressed as mean ± standard error or number (%)
  3. a The Mann-Whitney U test was used for this analysis
  4. b Primary treatments refers to the first cancer treatments
  5. c Incidence of VTE after diagnosis of endometrial cancer was evaluated
  6. d Neoadjuvant chemotherapy followed by laparotomy or laparoscopy was considered as surgery
  7. e The Fisher’s exact test was used for this analysis